Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three and nine-month periods ended September 30, 2025 and 2024, were as follows (in thousands):

	Three Months Ended						Three Months Ended
	September 30, 2025						September 30, 2024
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	366,425	$	17,732	$	384,157	$	322,855	$	16,990	$	339,845
Cost of sales standard(1)		144,299		4,258				137,530		4,594
Cost of sales other(2)		47,324		1,865				37,531		2,655
Selling, general and administrative expenses		113,835		5,966				90,409		9,235
Research and development expenses		23,157		809				19,727		800
Other operating expenses(3)		32		—				103		—
Income from operations	$	37,778	$	4,834	$	42,612	$	37,555	$	(294)	$	37,261
Total other expense — net						(4,072)						(604)
Income before income taxes					$	38,540					$	36,657

	Nine Months Ended						Nine Months Ended
	September 30, 2025						September 30, 2024
	Cardiovascular		Endoscopy		Consolidated		Cardiovascular		Endoscopy		Consolidated
Net sales	$	1,069,163	$	52,807	$	1,121,970	$	964,044	$	37,312	$	1,001,356
Cost of sales standard(1)		430,449		12,963				411,088		10,959
Cost of sales other(2)		129,057		6,583				105,661		3,298
Selling, general and administrative expenses		322,482		17,902				273,343		15,314
Research and development expenses		68,417		2,394				60,286		1,986
Other operating expenses(3)		1,198		—				292		—
Income from operations	$	117,560	$	12,965	$	130,525	$	113,374	$	5,755	$	119,129
Total other expense — net						(10,648)						(2,281)
Income before income taxes					$	119,877					$	116,848

(1) Cost of sales standard represents costs of goods sold measured at the internal standard cost for production of inventory. Inventory standard costs include material, labor and manufacturing overhead.

(2) Cost of sales other for all segments includes amortization expense associated with our developed technology and license agreement intangible assets, freight and handling associated with shipments to customers, provisions based on estimated excess, slow moving and obsolete inventories, manufacturing and price variances, and royalties.

(3) Other operating expenses include contingent consideration expense (benefit) related to the changes in fair value of contingent payments associated with acquisitions.

Total depreciation and amortization by operating segment for the three and nine-month periods ended September 30, 2025 and 2024, consisted of the following (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2025		2024		2025		2024
Cardiovascular	$	29,055	$	24,025	$	84,792	$	71,377
Endoscopy		2,261		2,378		6,837		2,716
Total	$	31,316	$	26,403	$	91,629	$	74,093